TEVA

Teva Pharmaceutical Industries Limited · NYSE · Healthcare · USD · 10-K for 2025, filed 2026-02-03

Figures on this page computed 2026-11-08 13:00 UTC

Last close

41.85USD

Market data, 2026-11-04

Except where said otherwise: 10-K for 2025, filed 2026-02-03

34.6xP/E
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001193125-26-034532
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-03
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001193125-26-034532
Reported in
USD
- 10-K for 2025, filed 2026-02-03
- 10-K for 2025, filed 2026-02-03
- 10-K for 2025, filed 2026-02-03
- 10-Q for 2025, filed 2026-11-03
- 10-K for 2025, filed 2026-02-03
- 10-Q for 2025, filed 2026-11-03
The filing itself
8.2%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-034532
Reported in
USD
- 10-K for 2025, filed 2026-02-03
- 10-K for 2025, filed 2026-02-03
The filing itself
6.7%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-034532
Reported in
USD
- 10-K for 2025, filed 2026-02-03
- 10-K for 2025, filed 2026-02-03
The filing itself
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001193125-26-034532
Reported in
USD
- 10-K for 2025, filed 2026-02-03
- 10-Q for 2025, filed 2026-11-03
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Safety is the furthest below its sector's middle: 0.29 against 0.53 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

All from 100

lens 2 of 9

Sales

78.8

2016-12-31 to 2025-12-31100 at the start78.8

Sales: 100.00 on 2016-12-31 to 78.79 on 2025-12-31, down 21%.

Profit

429

2016-12-31 to 2025-12-31100 at the start429

Profit: 100.00 on 2016-12-31 to 428.57 on 2025-12-31, up 329%.

Shares in issue

121,019,771

2016-12-31 to 2025-12-31100 at the start121,019,771

Shares in issue: 100.00 on 2016-12-31 to 121019771.07 on 2025-12-31, up 121019671%.

Sales is at 79, Profit is at 429, Shares in issue is at 121019771, against 100 in 2016.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-02-03

Sales, where the first year is 10079
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-034532
Reported in
USD
The filing itself
Profit, where the first year is 100429
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-034532
Reported in
USD
The filing itself
Shares in issue, where the first year is 100121,019,771
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-034532
Reported in
USD
The filing itself